Issue 24, 2022

Benzimidazole-based ionic and non-ionic organoselenium compounds: innovative synthetic strategies, structural characterization and preliminary anti-proliferative activities

Abstract

The design of and synthetic routes to three different classes of structurally innovative ionic (7a and 7b, 8a–8c and 9a–9c) and non-ionic organoselenium compounds (10a–10c) containing benzimidazole pharmacophores and substituted phenyl rings (4-H, 4-NO2 and 4-OMe) are described. The ionic sets of compounds consisted of benzimidazole-fused cyclic selenazolium selenocyanates (7a and 7b), selenazinium selenocyanates (8a–8c) and acyclic benzimidazolium selenocyanates (9a–9c). The final compounds could be synthesized effectively from the suitable benzimidazole derivatives in multi-step synthesis and the selenium incorporation was done using potassium selenocyanate. All the purified compounds were characterized by analytical methods and the structure of a representative selenazolium selenocyanate (7b) was further confirmed by single-crystal X-ray diffraction study. A mechanistic outline was proposed for the cyclized products. Considering the hints about the anti-cancer and chemopreventive activities of reported organoselenocyanates, the innovative sets of synthesized ionic and non-ionic compounds were evaluated for their preliminary anti-proliferative activities against highly aggressive triple-negative breast cancer (MDA-MB-231, human breast adenocarcinoma) cells. Interestingly, our in vitro studies revealed the highly enhanced anti-proliferative activities of non-ionic organoselenocyanates over ionic organoselenium compounds in general and the significantly high selectivity of the lead compound 10c having the 4-NO2 group towards cancer cells over normal cells. The lead compound exhibited potent anti-migratory activity, induced dose-dependent cell cycle arrest in the G1 phase and modulated the expression levels of key cancer-marker proteins. Our results reveal that 10c exhibits anti-proliferative activity most likely by arresting cells in the G1 phase and by enhancing intracellular ROS levels in triple-negative breast cancer cells.

Graphical abstract: Benzimidazole-based ionic and non-ionic organoselenium compounds: innovative synthetic strategies, structural characterization and preliminary anti-proliferative activities

Supplementary files

Article information

Article type
Paper
Submitted
17 Mar 2022
Accepted
10 May 2022
First published
11 May 2022

New J. Chem., 2022,46, 11910-11926

Benzimidazole-based ionic and non-ionic organoselenium compounds: innovative synthetic strategies, structural characterization and preliminary anti-proliferative activities

K. Banerjee, D. Bhattacherjee, K. Raina, R. P. Thummer and K. P. Bhabak, New J. Chem., 2022, 46, 11910 DOI: 10.1039/D2NJ01322C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements